[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Region Västerbotten\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":118},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,70,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100638658","risk-factors-associated-with-infraposition-of-implant-supported-single-crowns-in-the-anterior-maxilla-100638658",false,"NCT07593131","Risk Factors Associated With Infraposition of Implant Supported Single Crowns in the Anterior Maxilla","Risk Factors Associated With Infraposition of Single-tooth Implants in the Anterior Maxilla","Inclusion Criteria:\n\nPatients over 18 years of age who had received an Implant Supported Single Crown in the anterior maxilla (canine to canine) were eligible for inclusion.","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","OBSERVATIONAL","Losing a tooth in the front part of the upper jaw can affect both appearance and the ability to bite and chew. Treatment to replace missing teeth is therefore often required. Such treatment may be burdensome for the individual and can involve substantial costs for both the patient and society. A common treatment option is placement of a titanium screw (dental implant) in the jawbone. After a healing period, the implant is restored with a crown designed to resemble a natural tooth.\n\nReplacement of missing teeth with dental implants in the anterior maxilla can be particularly challenging. Over time, the crown of an implant may appear shorter than the adjacent natural teeth. This occurs because natural teeth may continue to change position throughout adulthood, whereas dental implants remain fixed within the bone. As a result, the implant-supported crown may appear to sink relative to neighboring teeth, a phenomenon referred to as infraposition. The prevalence of infraposition and the factors contributing to its development are not yet fully understood.\n\nThe aim of this study is to determine the frequency and extent of infraposition and to identify potential contributing factors in individuals treated with a single implant-supported crown in the anterior maxilla. The study also aims to evaluate the aesthetic outcome after treatment from both the patient and the clinician perspective.\n\nThe study hypothesis is that infraposition occurs in a clinically relevant proportion of patients and that certain factors, such as age at implant placement or individual dental characteristics, may increase the likelihood of its occurrence. It is further hypothesized that infraposition of the implant-supported crown may influence aesthetic appearance and that these changes may be perceived differently by patients and dental professionals.\n\nThrough longitudinal follow-up and comparison of repeated digital scans, the study seeks to improve understanding of the occurrence of infraposition, its contributing factors, and its potential impact on the aesthetic outcome of implant-supported crowns over time.",[24,25],"Infraposition","Estethics",[27,28,29,30,31,32,24],"Dental Implants","Esthetics","Dental","Dental Impression Technique","Imaging, three dimensional","Positional change","RECRUITING","2026-05-11",{"date":36,"type":37},"2026-05-18","ACTUAL",{"date":39,"type":37},"2021-12-14",{"date":41,"type":20},"2036-12-14",{"name":43,"class":44},"Region Västerbotten","OTHER_GOV",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100591733","male-lichen-sclerosus---risk-factors-treatment-and-impact-on-quality-of-life-100591733","NCT06984263","Male Lichen Sclerosus - Risk Factors, Treatment, and Impact on Quality of Life","Inclusion Criteria for patients with LS (LS Urology and LS dermatology):\n\n* Biologically male\n* ≥18 years old\n* Referred to the dermatology department or the urology department in Västerbotten and diagnosed with LS.\n* Must be able to read and write Swedish to fill in questionnaire and informed consent.\n\nInclusion criteria for control group \"Controls - Urology\":\n\n* Biologically male\n* ≥18 years old\n* Phimosis without LS, treated with circumcision at the urology department in Västerbotten\n* Must be able to read and write Swedish to fill in questionnaire and informed consent.\n\nInclusion criteria for control group \"Controls - General Population\":\n\n* Biologically male with male genitalia\n* ≥18 years old\n* No genital symptoms\n* Must be able to read and write Swedish to fill in questionnaire and informed consent.\n\nExclusion Criteria for all groups:\n\n* Age under 18 years old\n* Not able to read and write in Swedish.\n* Unable to leave an informed consent to participate.",true,"MALE",{"count":55,"type":20},300,"This observational study aims to evaluate routine treatment outcomes in men with lichen sclerosus (LS), including a long-term follow-up to assess disease progression and histopathological changes. The study also investigates potential risk factors for LS and the disease's impact on quality of life and sexual health.",[58],"Lichen Sclerosus",[60],"lichen sclerosus","2026-02-09",{"date":63,"type":37},"2026-02-10",{"date":65,"type":37},"2025-10-06",{"date":67,"type":20},"2038-10",{"name":43,"class":44},1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":45},"100559524","phase-3-evaluation-of-psma-pet-and-mpmri-in-high-risk-prostate-cancer---using-histopathologic-validation-100559524","NCT06565247","Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation","Inclusion Criteria:\n\n1. Histologically confirmed prostate cancer planned to be treated with radical prostatectomy\n2. PSMA-PET\u002FCT conducted as part of the clinical management for the existing prostate cancer.\n3. ≥4 weeks since last biopsy of the prostate\n4. One or more of the following criteria\n\n   1. cT3, or high suspicion of extra prostatic growth on mpMRI\n   2. Gleason score ≥8\n   3. PSA 20-49 ng\u002Fml\n5. \\>18 years\n6. Given a written consent to participate in the trial\n\nExclusion Criteria:\n\n1. Non-MR-safe implants or another contraindication to MRI or PET\n2. Claustrophobia\n3. Unfit for MRI or PET\u002FMRI examination for any other reason, e.g., back pain\n4. WHO PS \\>1\n5. Patients treated with neoadjuvant\u002Fconcomitant anti-testosterone treatment (surgical or medical castration or anti-androgens)\n6. TUR-P within 6 months\n7. Metastatic disease in skeleton, parenchymal organs, or lymph nodes outside the pelvis.\n8. Patients with previous diagnosis of other malignant disease. Exceptions could be made for basal cell carcinoma of the skin or progression free survival at least 10 years after any previous tumour.\n9. Creatinine clearance \\\u003C 30ml\u002Fmin (acc. to http:\u002F\u002Fwww.fass.se\u002FLIF\u002Fproduktfakta-\u002Fkreatinin.jsp)\n10. Tinnitus or severe hearing loss",{"count":19,"type":20},"INTERVENTIONAL",[79],"PHASE3","In this trial the connection between image properties (mpMRI and PSMA-PET) and tissue properties (molecular and histopathology) will be investigated in order to improve diagnostics and image-based treatment guidance of prostate cancer.",[82],"Prostate Cancer","2025-03-03",{"date":85,"type":37},"2025-03-04",{"date":87,"type":37},"2024-10-14",{"date":89,"type":20},"2031-12",{"name":43,"class":44},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":99,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":102,"conditions":103,"keywords":107,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":69},"100505023","prognostic-and-diagnostic-added-value-of-medical-imaging-in-gynecological-cancer-prodigyn-100505023","NCT05855941","Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)","Prognostic and Diagnostic Added Value of Medical Imaging in Staging and Treatment Planning of Gynecological Cancer (PRODIGYN)","PRODIGYN","Inclusion Criteria:\n\n* Previously untreated primary cervical, endometrial, or strongly suspected epithelial ovarian cancer.\n* Known clinical FIGO stage.\n* \\>18 years old.\n* No other known current or previous malignancy within the last 10 years.\n\nExclusion Criteria:\n\n* Imaging findings suggestive of other primary malignancy.\n* Previously included suspected epithelial ovarian cancer, later confirmed to be other diagnosis than epithelial ovarian cancer or \"cancer abdominis\".\n* MRI incompatible devices or patient unable to undergo MRI.","FEMALE",{"count":101,"type":20},120,"The goal of this observational study is to learn about the added diagnostic and prognostic value of advanced medical imaging procedures in cervical cancer, endometrial cancer and ovarian cancer. The main questions it aims to answer are:\n\n* Does advanced medical imaging predict survival?\n* Can advanced medical imaging improve radiotherapy target planning?\n* Are advanced medical imaging results associated with risk markers found in tumor tissue?\n\nParticipants will\n\n* Undergo four additional imaging procedures, as compared to clinical routine examinations, two at baseline and two after three months.\n* Be subject to clinical follow-up for five years.",[104,105,106],"Cervix Cancer","Endometrial Cancer","Epithelial Ovarian Cancer",[108,109,104,105,106],"Positron Emission Tomography-Computed Tomography","Magnetic Resonance Imaging","2024-12-10",{"date":112,"type":37},"2024-12-16",{"date":114,"type":37},"2023-05-23",{"date":116,"type":20},"2032-05",{"name":43,"class":44},""]